Goal and results of the COSS study;Ziele und ergebnisse der COSS-studien

Handchirurgie Mikrochirurgie Plastische Chirurgie

Volumn 36, Issue 5, 2004, Pages 282-288

  Flege, Silke ^a   Bielack, S ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cooperative Osteosarcoma Study Group; Osteosarcoma; Therapy strategies

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MEDRONATE TECHNETIUM TC 99M; METHOTREXATE;

ADOLESCENT; ADULT; AUSTRIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; COOPERATIVE OSTEOSARCOMA STUDY GROUP; DATA BASE; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; INFORMATION PROCESSING; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REVIEW; SWITZERLAND; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; GERMANY; HAND; HUMANS; IFOSFAMIDE; METHOTREXATE; MULTICENTER STUDIES; NEOADJUVANT THERAPY; NEOPLASM STAGING; OSTEOSARCOMA; PATIENT CARE TEAM; PROGNOSIS; SURVIVAL RATE;

EID: 7544222647     PISSN: 07221819     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821288     Document Type: Review

References (30)

1. Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J: Renal function following combination chemotherapy with Ifosfamide and Cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32: 93-96
2. Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K: Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties? Eur J Cancer 1996; 32: 1652-1660
3. Bielack SS, Erttmann R, Winkler K, Landbeck G: Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-882
4. Bielack SS, Jürgens H: In reply to "Comment on 'Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1.702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols' by Ferrari et al.". J Clin Oncol 2002; 20: 2910
5. Bielack S, Kempf-Bielack B, Branscheid D, Helmke K, Kabisch H, Kotz R, Jürgens H: Relapsed osteosarcoma: An analysis of 576 Cooperative Osteosarcoma Study Group (COSS) patients. Abstract, Chicago: 39th Annual Meeting of the American Society of Clinical Oncology, 2003
6. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002; 20: 776-790
7. Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner GU, Fuchs N, Göbel U, Graf N, Heise U, Helmke K, von Hochstetter AR, Jürgens H, Maas R, Münchow N, Salzer-Kuntschik M, Treuner J, Veitmann U, Werner M, Winkelmann W, Zoubek A, Kotz R: Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Pädiatr 1999; 211: 260-270
8. Bielack SS, Kempf-Bielack B, Winkler K: Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996; 15: 683-684 (letter)
9. Bielack SS, Wulff B, Delling G, Göbel U, Kotz R, Ritter J, Winkler K: Osteosarcoma of the trunk treated by multimodal therapy: Experience of the cooperative osteosarcoma study group COSS. Med Pediatr Oncol 1995; 24: 6-12
10. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106-120
11. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Brach Del Prever A, Fagioli F, Comandone A, Bacci G: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715
12. Fletcher CDM, Unni KK, Mertens F (Eds.): WHO Classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002
13. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-899
14. Graf, N, Winkler K, Betlemovic M, Fuchs N, Bode U: Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-1451
15. Kaatsch P, Kaletsch U, Spix C, Michaelis J: Jahresbericht 1998: Deutsches Kinderkrebsregister. Mainz, Germany, Johannes-Gutenberg-Universität, Institut für Medizinische Statistik und Information; 1999
16. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS: Primary metastatic osteosarcoma: Presentation and outcome of 202 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols. J Clin Oncol 2003; 21: 2011-2018
17. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA et al.: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremities. N Engl J Med 1986; 314: 1600-1606
18. Meyers PA, Schwartz CL, Bernstein M et al.: Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event-free survival (EFS) in localized osteosarcoma (OS). Proceedings of the American Society of Clinical Oncology 2001; 20: 1463 (abstract)
19. Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jürgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W, Bielack SS: Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2003; 21: 334-341
20. Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, Jürgens H, Kotz R, Winkelmann W, Bielack SS: Osteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer 2002; 94: 1069-1077
21. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M: The relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705
22. Picci P, Vanel D, Briccoli A, Talle K, Haakenaasen U, Malaguti C, Monti C, Ferrari C, Bacci G, Saeter G, Alvegard TA: Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12: 1601-1604
23. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Morcove RC, Lane JM, Mehta B, Urban C: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230
24. Sanders TG, Parsons TW III: Radiographic imaging of musculoskeletal neoplasia. Cancer Control 2001; 8: 221-231
25. Sinha BK, Politi PM: Anthracyclines. Cancer Chemother Biol Response Modif 1990; 11: 45-57
26. Smith MA, Ungerleider RS, Horowitz ME, Simon R: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83: 1460-1470
27. Sobin LH, Wittekind C: UICC TNM classification of malignant tumors. New York: 6th ed. Wiley, 2002
28. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, Berger J, Ritter J, Jurgens H, Gerein V et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-337
29. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Gobel U et al.: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/ Austrian study. J Clin Oncol 1984; 2: 617-624
30. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, Jurgens H, Ritter J, Kusnierz-Glaz C, Erttmann R et al.: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 1990; 66: 1703-1710